Pemetrexed Disodium

Name: Pemetrexed Disodium
SKU: P1849
Availability: InStock

Product ID P1849

Cas No. 150399-23-8

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Add to Wishlist

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

Pemetrexed is an antifolate anticancer chemotherapeutic that inhibits thymidylate synthase. Pemetrexed is currently in clinical trials as a potential treatment for ovarian cancer and lung adenocarcinoma. Pemetrexed may also inhibit other enzymes involved in folate metabolism, including serine hydroxymethyltransferase (SHMT), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). In vitro, Pemetrexed induces activation of caspases 2, 3, 8, and 9 and increases levels of Bax, Fas, death receptor 4 (DR4), and death receptor 5 (DR5), resulting in caspase-mediated apoptosis.

Product Info

Cas No.	150399-23-8
Purity	≥98%
Formula	C₂₀H₁₉N₅Na₂O₆
Formula Wt.	471.37
IUPAC Name	disodium;(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
Solubility	Water
Appearance	White to off white powder

Shipping and Storage

Store Temp	4°C
Ship Temp	Ambient

Downloads

MSDS	P1849 MSDS PDF
Info Sheet	P1849 Info Sheet PDF

References

Walters CL, Arend RC, Armstrong DK, et al. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol. 2013 Nov;131(2):493-8. PMID: 23863359.

Lau DH, Moon J, Davies AM, et al. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin Lung Cancer. 2013 Jul;14(4):351-5. PMID: 23415808.

Yang TY, Chang GC, Chen KC, et al. Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. Mol Carcinog. 2013 Mar;52(3):183-94. PMID: 22086658.

Su L, Liu G, Hao X, et al. Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. Eur J Cancer. 2011 Nov;47(16):2471-8. PMID: 21726997.

Daidone F, Florio R, Rinaldo S, et al. In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed. Eur J Med Chem. 2011 May;46(5):1616-21. PMID: 21371789.

Joerger M, Omlin A, Cerny T, et al. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets. 2010 Jan;11(1):37-47. PMID: 19839929.

Blackwood E, Epler J, Yen I, et al. Combination drug scheduling defines a “window of opportunity” for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. Mol Cancer Ther. 2013 Oct;12(10):1968-1980. PMID: 23873850.